bpc 157 lyme disease A Functional Medicine Guide to Manage Autoimmune Diseases in Lyme

Initial treatment for patients with neurological involvement follows British National Formulary (BNF) guidance: Hydroxocobalamin 1 mg intramuscularly on alternate days for approximately 2-3 weeks (or until no further improvement) Maintenance therapy then consists of hydroxocobalamin 1 mg intramuscularly every two months Hydroxocobalamin is preferred over cyanocobalamin in the UK due to superior retention and fewer injections required

Proper usage guidelines can help maximize potential benefits while minimizing risks

The most likely range of outcomes, based on how analogous FDA processes have unfolded historically, is somewhere between "some peptides moved to a more permissive category, others kept on the restricted list pending further data" and "all peptides kept on the restricted list pending further data, with specific data requests for each." A blanket lifting of all restrictions is the least likely outcome and would be an unusual departure from how the agency typically handles incomplete safety data

Trials conducted in collaboration between clinicians and basic scientists, such as exploratory studies and assessments of biomedical engineering therapy

Use them at different times or on alternating days

The test administrators may have special preparation instructions as well